TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business Update
August 05 2022 - 7:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a
conference call will be held on Monday, August 8, 2022 at 8:30 AM
ET to discuss results for the second quarter of 2022. Michael S.
Weiss, Executive Chairman and Chief Executive Officer, will host
the call.
In order to participate in the conference call, please call
1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.),
Conference Title: TG Therapeutics. A live webcast of this
presentation will be available on the Events page, located within
the Investors & Media section, of the Company's website at
www.tgtherapeutics.com. An audio recording of the conference call
will also be available for replay at www.tgtherapeutics.com, for a
period of 30 days after the call.
TG Therapeutics will announce its financial results for this
period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS TG Therapeutics is a
biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for B-cell diseases. In
addition to a research pipeline including several investigational
medicines, TG has completed a Phase 3 program for ublituximab, an
investigational glycoengineered monoclonal antibody that targets a
unique epitope on CD20-expressing B-cells, to treat patients with
relapsing forms of multiple sclerosis (RMS). For more information,
visit www.tgtherapeutics.com, and follow us on
Twitter @TGTherapeutics and Linkedin.
CONTACT:
Investor Relations
Email: ir@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option
6
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Sep 2023 to Sep 2024